Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis

Am J Respir Crit Care Med. 2005 Nov 1;172(9):1128-32. doi: 10.1164/rccm.200407-989OC. Epub 2005 Aug 11.

Abstract

Rationale: High-resolution computed tomography (HRCT) has been suggested as a potential outcome surrogate for cystic fibrosis (CF) lung disease. An important attribute of a valid outcome surrogate is that the surrogate reflects true clinical outcomes.

Objectives: We performed this study to validate HRCT, a proposed surrogate outcome measure for CF lung disease, against a true clinical outcome, the number of respiratory tract exacerbations occurring in 2 yr, and to assess the correlation of CT scores and pulmonary function tests (PFTs) with this clinical outcome.

Methods: CTs and PFTs were performed on 6- to 10-yr-old children at the beginning and end of a 2-yr study during which the number of exacerbations were recorded. Spearman correlations and Poisson models were used to assess the correlation of the number of exacerbations with baseline values and changes in PFTs and CT scores.

Measurements and main results: Nine of 61 subjects had a total of 22 respiratory tract exacerbations. At baseline, PFTs and four CT scores showed significant correlation with number of exacerbations, but no variable by itself predicted exacerbations with high accuracy. For change over the 2-yr period, three CT scores showed significant correlation with exacerbations, whereas no PFTs showed significant correlation.

Conclusion: This is the first study showing correlation between CT and a true clinical outcome. Change in CT scores correlates moderately well with the number of exacerbation. Poor correlation between change in FEV1 and exacerbations suggests that HRCT may be a more appropriate outcome surrogate for longitudinal studies of young children.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Anti-Bacterial Agents / administration & dosage
  • Child
  • Cystic Fibrosis / complications
  • Cystic Fibrosis / diagnostic imaging*
  • Cystic Fibrosis / drug therapy
  • Deoxyribonuclease I / therapeutic use
  • Female
  • Hospitalization
  • Humans
  • Infusions, Intravenous
  • Lung / diagnostic imaging*
  • Male
  • Reproducibility of Results
  • Respiration Disorders / etiology*
  • Respiratory Function Tests
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • DNASE1 protein, human
  • Deoxyribonuclease I